Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,501.65 -12.72 -0.08%
S&P 500 1,875.39 -4.16 -0.22%
NASDAQ 4,126.97 -34.49 -0.83%
Ticker Volume Price Price Delta
STOXX 50 3,206.08 30.11 0.95%
FTSE 100 6,723.86 49.12 0.74%
DAX 9,637.23 93.04 0.97%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,562.80 53.16 0.24%

Ignyta Appoints Dr. Tom Huizinga to Scientific Advisory Board



  Ignyta Appoints Dr. Tom Huizinga to Scientific Advisory Board

Business Wire

SAN DIEGO -- March 20, 2013

Ignyta, Inc., the personalized medicine company dedicated to improving the
diagnosis and treatment of patients with rheumatoid arthritis, lupus and other
autoimmune diseases, announced today the appointment of Professor Tom
Huizinga, Chairman of the Department of Rheumatology at Leiden University
Medical Center (LUMC), to its Scientific Advisory Board.

“Ignyta is making a concerted effort to work with the leading rheumatologists
in the world as we seek to advance personalized medicine solutions for
rheumatologic and autoimmune disorders,” said Jonathan Lim, M.D., co-founder,
chairman and CEO of Ignyta. “Tom Huizinga is one of the most published and
cited authors in the field of rheumatology, particularly on the topic of
detection of early stage rheumatoid arthritis where Ignyta has a strong
focus.”

Tom Huizinga is a Professor and Chairman of the Department of Rheumatology at
Leiden University Medical Center (LUMC) in Leiden, Netherlands. Professor
Huizinga was a member of the Annual Meeting Planning Committee of the American
College of Rheumatology (ACR) from 2000 to 2003, and the Annual Meeting
Planning Committee of the European League Against Rheumatism (EULAR) from 2004
to 2007. In 2006, he was appointed as a member of the Henry Kunkel Society,
New York. In 2005/2006, he served as a member of the "Verkenningscommissie
Multifactoriele Aandoeningen in het Genomics Tijdperk" of the Royal Dutch
Academy of Sciences.

Professor Huizinga has won various prizes throughout his academic career and
has published over 500 peer-reviewed papers in the national and international
literature. He is member of the editorial boards of Plos Medicine, Annals of
Rheumatic Diseases, Arthritis and Rheumatism, Current Rheumatology Reviews,
Genes and Immunity, International Journal of Advances in Rheumatology, Joint
Bone Spine, Revue du Rheumatism International Edition, Current Rheumatology
Reviews, Clinical and Experimental Rheumatology.

Professor Huizinga graduated from the University of Amsterdam Medical School,
studied at Dartmouth Medical School, and returned to the Netherlands to train
in internal medicine/rheumatology.

About Ignyta, Inc.

Ignyta, Inc., located in San Diego, California, is a personalized medicine
company developing revolutionary new products and services to customize
diagnosis and treatment of patients with rheumatoid arthritis, lupus and other
autoimmune diseases.

The company was launched in August 2011 by Jonathan E. Lim, M.D., former
president, CEO, and board director of Halozyme Therapeutics, Inc., and Gary S.
Firestein, M.D., director of the Clinical and Translational Research Institute
and Dean and Associate Vice Chancellor of Translational Medicine at UC San
Diego. Ignyta is a trailblazer in the application of “omics” technologies
integrated with bioinformatics to the development and commercialization of
novel biomarkers and tests for diagnostic and therapeutic applications in
autoimmune diseases.

The scientific discoveries that fueled the founding of Ignyta were published
in July 2012 in the Annals of the Rheumatic Diseases (http://bit.ly/QOZ8Zr).
In 2012, the company successfully closed a $5.5 million Series B financing led
by City Hill Ventures, LLC (http://www.cityhillventures.com/) and Colt
Ventures (http://www.coltventures.com/). In 2012 and 2013, the company
received $500,000 and $1,000,000 capital term loans, respectively, from
Silicon Valley Bank (http://www.svb.com/). For more information, please visit:
www.ignyta.com.

Contact:

Ignyta Media and Investor Contact:
Zachary Hornby
zh@ignyta.com
858-369-5732
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement